Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Iterum Therapeutics PLC
NASDAQ ITRM
Data sourced from
and
and
Iterum Therapeutics PLC Revenue Per Share for the quarter ending March 31, 2024: USD 0.00
Iterum Therapeutics PLC Revenue Per Share is USD 0.00 for the quarter ending March 31, 2024, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.
-
Iterum Therapeutics PLC Revenue Per Share for the quarter ending March 31, 2023 was USD 0.00, a 0.00% change year over year.
-
Iterum Therapeutics PLC Revenue Per Share for the quarter ending March 31, 2022 was USD 0.00, a 0.00% change year over year.
-
Iterum Therapeutics PLC Revenue Per Share for the quarter ending March 31, 2021 was USD 0.00, a 0.00% change year over year.
-
Iterum Therapeutics PLC Revenue Per Share for the quarter ending March 31, 2020 was USD 0.00, a -100.00% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ITRM
| CEO | Mr. Corey N. Fishman |
| IPO Date | May 25, 2018 |
| Location | Ireland |
| Headquarters | Fitzwilliam Court, Dublin, Ireland, 2 |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Key trends
Similar companies
Hoth Therapeutics Inc
NA
NA
StockViz Staff
September 16, 2024
Any question? Send us an email